Valuation: Protalix BioTherapeutics, Inc.

Market Cap 193M 0 170M 158M 145M 272M 18.47B 277M 1.87B 734M 9.16B 726M 710M 31.65B P/E 2026 *
12.3x
P/E 2027 * 48x
Enterprise Value 193M 0 170M 158M 145M 272M 18.47B 277M 1.87B 734M 9.16B 726M 710M 31.65B EV / Sales 2026 *
2.47x
EV / Sales 2027 * 2.86x
Free-Float
96.12%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 30/06/2019
Director of Finance/CFO 57 24/08/2025
Chief Tech/Sci/R&D Officer - 01/06/2024
Director TitleAgeSince
Director/Board Member 73 01/07/2008
Director/Board Member 82 01/11/2014
Director/Board Member 59 30/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+3.29% - - 193M
+1.95%+3.71%+50.84%+165.87% 1,068B
+0.93%+7.27%+61.74%+54.08% 641B
+3.42%+3.55%+40.67%+75.80% 454B
+2.17%+10.22%+41.17%+36.56% 351B
+1.46%+3.87%+39.70%+44.49% 299B
+0.40%+3.59%+19.93%+17.02% 266B
+2.73%+3.50%-25.66%-36.53% 220B
+4.09%+6.62%+29.61%+65.20% 203B
+2.57%+2.36%+17.99%+73.51% 162B
Average +2.00%+2.76%+30.67%+55.11% 407.04B
Weighted average by Cap. +2.04%+2.85%+40.19%+80.25%

Financials

2026 *2027 *
Net sales 78.3M 0 68.71M 63.99M 58.85M 110M 7.48B 112M 759M 297M 3.71B 294M 288M 12.82B 67.56M 0 59.29M 55.22M 50.79M 95.2M 6.45B 96.83M 655M 256M 3.2B 254M 248M 11.06B
Net income 15.72M 0 13.8M 12.85M 11.82M 22.15M 1.5B 22.53M 152M 59.67M 745M 59.03M 57.75M 2.57B 4.07M 0 3.57M 3.33M 3.06M 5.74M 389M 5.84M 39.49M 15.46M 193M 15.29M 14.96M 667M
Net Debt - -
Logo Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.400USD
Average target price
11.00USD
Spread / Average Target
+358.33%

Quarterly revenue - Rate of surprise